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Background and Purpose: Patients undergoing carotid artery stenting (CAS) who
show low responsiveness to clopidogrel may have a higher risk of peri-procedural
embolic events. This study aimed to compare the effectiveness and safety of clopidogrel
and ticlopidine plus Ginkgo biloba in clopidogrel-resistant patients undergoing CAS.
Methods: In this multi-center, randomized, controlled trial, we used platelet reactivity test
to select patients undergoing CAS who showed clopidogrel resistance, and compared
treatments using clopidogrel and ticlopidine plus ginkgo. The primary outcome was the
incidence of new ischemic lesion in the ipsilateral hemisphere of CAS. Detection of
microembolic signal on transcranial Doppler was the secondary outcome. The clinical
outcomes were also monitored.
Results: This trial was discontinued after 42 patients were randomized after preplanned
interim sample size re-estimation indicated an impractical sample size. The primary
endpoint occurred in 12/22 patients (54.5%) in the clopidogrel group and 13/20 patients
(65.0%) in the ticlopidine–ginkgo group (P = 0.610). No significant differences in the
presence of microembolic signal (15.0 vs. 11.8%, P= 0.580), clinical outcomes (ischemic
stroke or transient ischemic attack, 0.0 vs. 5.5%; acute myocardial infarction 0.0 vs.
0.0%; all-cause death, 4.5 vs. 0.0%), or incidence of adverse events were found in
the two groups. In terms of resistance to clopidogrel, treatment with ticlopidine–ginkgo
significantly increased the P2Y12 Reaction Units (difference, 0.0 [−0.3–3.0] vs. 21.0
[6.0–35.0], P < 0.001).
Conclusions: In patients who showed clopidogrel resistance, ticlopidine–ginkgo
treatment was safe and increased P2Y12 Reaction Units; however, compared to
clopidogrel, it failed to improve surrogate and clinical endpoints in patients undergoing
Chung et al. Clopidogrel Resistance and Embolism in CAS
CAS. This multimodal biomarker-based clinical trial is feasible in neurointerventional
research.
Clinical Trial Registration: http://www.clinicaltrials.gov. Unique identifier:
NCT02133989.
Keywords: clopidogrel resistance, carotid stenosis, stroke, ischemia, ticlopidine, surrogate endpoint
INTRODUCTION
Antiplatelet agents are used to prevent stent thrombosis and
peri-procedural complications. The extent of inhibition of
platelet function by aspirin and clopidogrel differs among
individuals, and is related to recurrent cerebrovascular or
cardiovascular events during the use of antiplatelet agents.
While the Clopidogrel in High-risk patients with Acute Non-
disabling Cerebrovascular Events (CHANCE) trial showed that
in comparison with aspirin alone, combined treatment with
clopidogrel and aspirin decreases the 90-day risk of stroke
without increasing hemorrhage (1), it also showed that this effect
was not observed in CYP2C19 loss-of-function alleles (2).
Several studies have dealt with the association between
genetic (e.g., CYP2C19 loss-of-function alleles) and laboratory
(e.g., point-of-care tests for platelet aggregation) features of
clopidogrel resistance with cardiovascular events and stroke
FIGURE 1 | Measurement of laboratory outcomes. TCD, transcranial doppler; MES, microembolic signal. Written informed consent was obtained from the individual
appearing in this figure (top, middle).
in subjects receiving clopidogrel (3–8). However, few clinical
trials have been conducted to test antiplatelet strategies to
overcome clopidogrel resistance in patients with stroke or in
those who undergo carotid intervention. The use of P2Y12
receptor inhibitors other than clopidogrel, such as ticlopidine
or novel thienopyridines, could be a possible strategy against
clopidogrel resistance. The use of thienopyridine prodrugs with
more rapid and consistent actions (ticlopidine and prasugrel
have more pathways resulting in active metabolites and are
not deactivated by de-esterification) or direct-acting P2Y12
inhibitors (cangrelor and ticagrelor) could be alternatives to
the standard clopidogrel therapy (9). Although a recent clinical
trial tested the role of ticagrelor over aspirin in patients with
ischemic stroke/transient ischemic attack (TIA), further studies
are required to determine the optimal candidate for this novel
thienopyridine (10–12). Current guidelines do not recommend
the use of novel thienopyridines in patients with stroke.
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Biomarker-based diagnostic tests are increasingly being
used as surrogate markers in clinical trials in cancer (13),
cardiovascular disease (14), renal disease (15, 16), and
neurological disorder (17, 18), and they might add important
information from the neurointerventional point of view. In these
clinical trials, instead of clinical events, laboratory outcomes
were measured. In the present study, we selected three laboratory
outcomes (Figure 1). First, ischemic brain lesions on diffusion-
weighted images (DWIs), a marker of an increased risk of
cerebrovascular events in the International Carotid Stenting
Study (the recipient site) (19). Second, microembolic signals
(MES) on transcranial duplex (TCD) ultrasound monitoring,
which were related to clinical events and were used as markers
for antiplatelet effects in patients with carotid and intracranial
stenosis (migrating emboli) (20, 21). Third, the occurrence of
restenosis on follow-up carotid duplex (the donor site). As an
exploratory research, we tested the feasibility and usefulness of
this multidisciplinary and comprehensive laboratory approach
in a drug trial in the setting of a small number of patients with
few clinical events.
The usefulness of ticlopidine in patients with loss-of-
function CYP2C19 polymorphism carriers have been reported
(22). In addition, an experiment demonstrated augmented
antithrombotic and antiplatelet effects with ticlopidine and
Ginkgo biloba (23, 24). This trial aimed to evaluate the efficacy
and safety of ticlopidine plus Ginkgo biloba compared to
clopidogrel using surrogate biomarkers in patients showing
clopidogrel resistance who undergo carotid artery stent (CAS)
placement.
PATIENTS AND METHODS
Study Design and Oversight
The Clopidogrel Resistance and Embolism in Carotid Artery
Stenting (CRECAS) trial is a multicenter prospective,
randomized, open-label, blinded-endpoint trial. This study
is registered with ClinicalTrials.gov (identifier, NCT02133989).
Patients were enrolled from January 2014 through August
2017 at six sites in South Korea. The trial was approved by the
appropriate national regulatory authorities and relevant ethnics
committees at each participating site. All participants provided
written informed consents.
The executive committee was responsible for the overall
design, interpretation, and supervision of the trial, including the
development of the protocol and any amendments. The executive
committee was also responsible for ensuring the integrity of
the data, analysis, and presentation of results. An independent
data and safety monitoring committee reported to the executive
committee, and regularly assessed the safety outcomes, overall
study integrity, and study conduct. The sponsor had no influence
or involvement in the design, conduct, analysis, and decision to
terminate this trial. The sponsor was not part of the executive
committee.
Study Population
CRECAS-randomized patients had provided informed consent,
were scheduled for stent implantation owing to carotid stenosis
of 70% or more, and showed resistance to clopidogrel, defined
by platelet inhibition rate <20% measured by the VerifyNow
system (Accumetrics, San Diego, CA, USA) in patients taking a
clopidogrel dose of 75 mg/d for ≥7 days or 24 h after a loading
dose of 300mg for clopidogrel-naïve patients. Premedication
with clopidogrel 75mg for ≥7 days or 300mg for ≥24 h showed
similar platelet inhibition (25). All patients underwent brainMRI
including DWI within 1 months prior to carotid stenting.
Patients were not eligible for participation in the trial if
they were scheduled for other specific antiplatelet therapy
or anticoagulation therapy or for carotid, cerebrovascular, or
coronary revascularization that would require discontinuation
of the study treatment within 60 days after randomization.
Similarly, patients unable to undergo MR imaging; those
with hematologic abnormalities including neutrophil count
TABLE 1 | Baseline characteristics.
Clopidogrel
group (n = 22)
Ticlopidine–Ginkgo
group (n = 20)
P-value
Age 70.2 ± 8.2 74.7 ± 8.8 0.096
MALE
Body mass index 24.6 ± 3.3 23.7 ± 3.5 0.378
Systolic blood pressure 139.1 ± 20.1 135.0 ± 15.2 0.449
Diastolic blood
pressure
79.1 ± 11.9 74.4 ± 9.4 0.159
Presenting symptom 0.037
Asymptomatic 8 (36.4) 4 (20.0)
TIA 0 (0.0) 5 (25.0)
Stroke 14 (63.6) 11 (55.0)
Pre-treatment acute
ischemic lesion
12 (54.5) 13 (65.0) 0.355
MEDICAL HISTORY
Hypertension 17 (77.3) 16 (80.0) 0.565
Diabetes 14 (63.6) 8 (40.0) 0.111
Hyperlipidemia 10 (45.5) 8 (40.0) 0.483
History of CAD 2 (9.1) 3 (15.0) 0.453
History of stroke 9 (40.9) 6 (30.0) 0.34
LABORATORY VALUES
Neutrophil 56.4 ± 15.0 58.3 ± 15.8 0.696
Platelet 221.1 ± 59.7 214.8 ± 31.2 0.668
AST 22.8 ± 7.2 19.5 ± 5.1 0.086
ALT 25.8 ± 19.5 15.5 ± 6.5 0.027
PRU, initial 239.4 ± 56.4 248.5 ± 47.4 0.576
PRU (%), initial 5.7 ± 6.4 6.5 ± 8.0 0.734
Carotid stenosis side 0.199
Right 17 (85.0) 13 (68.4)
Left 3 (15.0) 6 (31.6)
Carotid stenosis,
degree
74.0 (70.0–88.75) 87.0 (80.0–90.0) 0.091
Carotid stenosis, ulcer 0 (0.0) 2 (10.5) 0.231
Carotid stenosis,
contralateral
8 (40.0) 6 (31.6) 0.416
TIA, transient ischemic attack; CAD, coronary artery disease; AST, aspartate
aminotransferase; ALT, alanine aminotransferase; PRU, P2Y12 reaction units.
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<1,500/µL, platelet count <100,000/µL, or AST/ALT >120 U/L;
and those who failed to understand or comply with the study
procedures or follow-up were excluded from the study.
Treatment
Eligible patients were randomly assigned in a 1:1 ratio to one of
two treatment groups, using random permuted blocks. Patients
were 1:1 randomized to clopidogrel 75mg daily or ticlopidine 250
mg/Ginkgo biloba 80mg twice daily, together with a daily dose of
aspirin 100mg for a 60-day treatment period. At the end of 24
weeks of study treatment, patients were treated at the discretion
of investigators and followed up.
Carotid stenting was performed according to the standardized
method by skilled and experienced operators. CAS was
performed as soon as possible in the clopidogrel group, and after
96 h of study medication in the ticlopidine–ginkgo group. All
patients received high-intensity statins according to the current
international guidelines before carotid stenting.
Endpoints
The primary endpoint for the trial was the presence of new
ischemic lesions in the ipsilateral hemisphere on DWI performed
within 24 h after carotid stenting. The predefined secondary
endpoints were the number and volume of new ischemic lesions
on DWI performed within 24 h after carotid stenting, and total
and malignant MES on TCD monitoring performed within
24 h after carotid stenting. TCD (Pioneer TC 8080; Nicolet
Vascular, Madison, WI, USA) was used to monitor both middle
cerebral arteries (MCAs) with insonation depths of 40–60mm for
microemboli using two 2-MHz probes fixed with a head frame
(Marc 500; Spencer Technologies, Northborough, MA, USA). All
MES’ were automatically saved to the computer hard disk for
review, and all analyses were performed blinded to individual
patient details. Bilateral recordings were performed for 30min,
with the patients in a supine position. Patients who had ≥1
MES during the 30min of TCD recording were classified as
MES positive. In the present study, we also measured malignant
MES, a larger-sized embolus requiring more clinical attention
(26, 27). MES’ with a relative energy index >1.0 were considered
malignant.
Other exploratory endpoints included ischemic stroke/TIA,
myocardial infarction, or death within 24 weeks after carotid
stenting. The safety endpoints included puncture-site hematoma,
hematological abnormalities, namely neutrophil count
<1,500/µL, platelet count <100,000/µL, or AST/ALT level >120
U/L. We also measured the changes of clopidogrel resistance, by
using the VerifyNow system. Clinical and laboratory follow-up
was conducted on Day 1, Day 7, Week 4, and Week 24 after
carotid stenting.
Statistical Analysis
A total of 82 patients were required to detect a hazard ratio
of 0.55, with a final two-sided significance level of 5 and 80%
power, as observed in a previous observational study (28). To
apply the 5% dropout rate, 86 patients were scheduled to be
enrolled. A single pre-specified interim analysis for efficacy and
futility was performed when half of the patients were enrolled
for sample size recalculation or early discontinuation of the
trial.
Statistical analyses were performed using PASW Statistics 18
(IBM, Chicago, IL, USA). Continuous variables are presented
as means with standard deviations, and categorical variables
are presented as frequencies and percentages. Variables were
compared by independent t-test, chi-square test, Mann–Whitney
U-test, and Fisher’s exact test. A two-tailed value of p < 0.05 was
considered statistically significant.
RESULTS
This trial was discontinued after prespecified interim analysis
for futility and power re-estimation after enrolment of 42
FIGURE 2 | Changes in P2Y12 Reaction Units. Change in P2Y12 Reaction Units in the (A) clopidogrel and (B) ticlopidine–ginkgo group.
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participants. The primary endpoint, new ischemic lesions in the
ipsilateral hemisphere of carotid stenting, was detected in 54.5%
(12 of 22) of patients in the clopidogrel group and 55.0% (11
of 20) of patients in the ticlopidine–ginkgo group. Based on
this result, the sample size was recalculated, and the estimated
number of patients required to show significant difference
in the two groups was 155,000 (Z-test with pooled variance
statistics; power, 0.80; two-sided significance level, 0.05, with
two independent proportions power analyses). PASS 12 (NCSS,
Kaysville, Utah, USA) software was used to perform the sample
size estimates. In addition, owing to the recently decreasing role
of carotid intervention in patients with asymptomatic carotid
stenosis, slow patient recruitment for the study was expected.
The executive committee concluded that it was impractical to
continue the study and decided to terminate it prematurely.
From June 2014 through October 2017, we recruited 42
patients, 22 of whom were assigned to the clopidogrel group and
20, to the ticlopidine–ginkgo group (Supplementary Table 1).
The baseline characteristics of the IIT-analysis population are
described in Table 1. Baseline characteristics were well-balanced
between the groups, except that compared to the clopidogrel
group (63.3%), more symptomatic (acute stroke or transient
ischemic attack) patients were enrolled in the ticlopidine–ginkgo
group (80.0%) (P = 0.037).
Before carotid stenting, acute ischemic lesions were found
in 12 (54.5%) patients in the clopidogrel group and 13 (65.0%)
patients in the ticlopidine–ginkgo group. The primary endpoint
of new ischemic lesion(s) in ipsilateral carotid stenting occurred
in 12 patients (54.5%) in the clopidogrel group and 11 patients
(55.0%) in the ticlopidine–ginkgo group (P = 0.610). There
were no significant differences between the groups with regard
to microembolic signal and carotid duplex imaging. However,
compared to persistent clopidogrel treatment, treatment with
ticlopidine–ginkgo for a median duration of 7 days significantly
improved P2Y12 Reaction Units (Figure 2). The details of
laboratory outcomes are demonstrated in Table 2. During a
median follow-up period of 178 days after carotid stenting,
one patient in the ticlopidine–ginkgo group experienced stroke
recurrence and one patient in the clopidogrel group died owing
to lung cancer. None of the patients enrolled in the study
experienced any hematologic or procedure-related adverse event.
The clinical and adverse events are summarized in Table 3.
DISCUSSION
The main findings of this trial are as follows: (1) clinical events
including ischemic stroke, acute myocardial infarction, and all-
cause death related to carotid stenting were rare, while surrogate
biomarker outcome events, detected by DWI and TCD, were
highly frequent; (2) the primary outcome, new ischemic lesion on
follow-up DWI, did not show significant difference between the
two study groups; (3) ticlopidine–ginkgo treatment significantly
improved drug resistance (P2Y12 Reaction Units). There were no
safety concerns identified within this small group of patients.
During the study screening period, 45.9% (106/231) of
patients treated with CAS showed clopidogrel resistance, which
TABLE 2 | Laboratory outcomes.
Clopidogrel
group
Ticlopidine–Ginkgo
group
P-value
Diffusion-weighted
image
(n = 22) (n = 20)
Pre-treatment acute
ischemic lesion
12 (54.5) 13 (65.0) 0.355
POST-TREATMENT NEW ISCHEMIC LESION
Stenting side 12 (54.5) 11 (55.0) 0.610
No. of small lesions 1.0 (0.0–4.0) 1.0 (0.0–3.0) 0.447
Presence of large
(>20mm) lesion
2 (9.1) 2 (10.0) 0.659
Contralateral side 6 (27.3) 5 (25.0) 0.574
No. of small lesion 0.0 (0.0–1.0) 0.0 (0.0–0.75) 0.422
Presence of large
lesion
0 (0.0) 0 (0.0) N/A
Posterior circulation 2 (9.1) 1 (5.0) 0.537
Microembolic signal (n = 20) (n = 17)
Presence 3 (15.0) 2 (11.8) 0.580
Malignant MES 0 0
Stenting side 2 (10.0) 2 (11.8) 0.633
No. MES 1/2 1/9
Contralateral side 1 (5.0) 0 (0.0) 0.541
No. MES 1 0
Carotid duplex
follow-up
(n = 13) (n = 14)
Presence of
restenosis
1 (7.7%) 2 (14.3) 0.586
Present of instant
thrombosis
0 0
P2Y12 Reaction
Units
(n = 21) (n = 19)
Improved, category
(>20%)
5 (23.8) 15 (78.9) 0.001
Improved, degree 0.0 (−3.0–3.0) 21.0 (6.0–35.0) <0.001
may be related to both genetic and non-genetic factors (e.g.,
concomitant use of statins, proton pump inhibitors, and presence
of diabetes) (29–33). The reported prevalence of clopidogrel
resistance in cerebrovascular intervention ranges from 28.8 to
65.8% (28, 34–36), and it is more prevalent in Asian individuals
(37).
The failure of this study could be attributed to the following
reasons. First, our study population showed a low rate of
vascular events (one stroke and one death) during the follow-
up period. With the advances in neurointerventional technique
and the use of high-intensity statins prior to CAS, the incidence
of periprocedural stroke/TIA has substantially decreased (38).
Another explanation is the short duration of follow-up in this
study. Most clinical trials testing the role of antiplatelet agents
in patients with high on-treatment residual platelet reactivity had
a long follow-up period (3, 5, 39, 40), while only peri-procedural
laboratory events were measured in the present trial. The third
reason is the differences in the baseline characteristics (more
asymptomatic patients in the clopidogrel group) and treatment
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TABLE 3 | Clinical and adverse events.
Clopidogrel
group (n = 22)
Ticlopidine–Ginkgo
group (n = 20)
P-value
CLINICAL EVENTS
Ischemic stroke/TIA 0 (0.0) 1 (5.0) 0.090
Acute myocardial
infarction
0 (0.0) 0 (0.0) NA
All-cause mortality 1 (4.5) 0 (0.0) 0.081
ADVERSE EVENTS
Hematologic adverse
event*
0 (0.0) 0 (0.0) NA
Procedure-related
adverse event
†
0 (0.0) 0 (0.0) NA
*Neutrophil <1500, PLT <100,000, AST/ALT >120.
†
Puncture-site hematoma requiring surgical intervention, anemia requiring transfusion,
prolongation of hospital admission.
protocol (stenting with a delay of at least 4 days of randomization
in the ticlopidine–ginkgo group) between the groups.
Although this trial failed to show the superiority of
ticlopidine–ginkgo over standard clopidogrel therapy in patients
with high on-treatment platelet reactivity undergoing CAS
placement, it has some clinical implications. Our results suggest
the possibility of clinical trials that use comprehensive surrogate
markers of three different sites (donor, migrating, and recipient).
Relatively small number of patients and a short follow-up
period may be required to evaluate the efficacy of drug
therapy. For example, the efficacy of antiplatelet agents has
been successfully tested using MES as a surrogate marker in
clinical trials with a small cohort (n = ∼100 patients) (20,
21). In addition, a recent meta-analysis showed that 1 out of
10 patients with silent DWI lesions during invasive vascular
or cardiac procedures experienced stroke or TIA (41). In the
present study, several patients showed embolism on DWI or
TCD measures, while only two patient showed a clinical event.
In this context, surrogate biomarker outcome-based clinical
studies may be helpful before starting a large clinical trial.
Further clinical trials using this approach and testing other
thienopyridines in various neurointerventional settings (e.g.,
endovascular aneurysmal repair) are warranted. Lastly, the
results of this trial showed considerable improvement in P2Y12
Reaction Units without hematologic or adverse effects by using
ticlopidine–ginkgo. Further studies with a larger cohort and
long-term follow-up are warranted.
This study has several limitations. First, the primary outcome
was the surrogate endpoint; further studies are required to
evaluate the long-term clinical efficacy of ticlopidine–ginkgo.
However, based on our results, it is unlikely that long-term
clinical efficacy events would differ between the groups. Second,
only Korean patients were included in the study; this may limit
the generalizability of our results, since a high prevalence of
clopidogrel resistance has been reported in the Asian population
(42). Third, more symptomatic patients with carotid stenosis
were enrolled in the ticlopidine–ginkgo group. Symptomatic
carotid stenosis is associated with a higher risk for recurrent
thromboembolism, and the imbalance in the baseline in this
trial may have affected the study endpoints. Finally, 96 h waiting
periods for the ticlopidine–ginkgo group could have affected the
study results.
CONCLUSION
Our findings indicate that a multimodal biomarker-based clinical
trial is feasible in research related to clinical stroke, with
more frequent endpoint events observed than those observed
from clinical outcomes. Compared to continued treatment
with clopidogrel, treatment with ticlopidine–ginkgo significantly
improved drug resistance. No adverse effects were observed
within this small group of patients. However, no difference was
observed in early surrogate biomarkers between the treatment
groups.
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